Ashfield Rebecca, Jakobsen Bent K
Avidex Ltd, 57C Milton Park, Abingdon, Oxon, OX14 4RX, UK.
IDrugs. 2006 Aug;9(8):554-9.
The last two decades have seen the development of an expanding array of monoclonal antibodies, which are proving to be effective treatments for both cancer and autoimmune disease. A related protein, the human T-cell receptor (TCR), is able to access a new range of targets for which antibodies are unsuitable, and is being developed as a new class of protein therapeutics. Similar to antibodies, TCRs have a specific target and therefore a limited potential for side effects; however, a possible drawback with these receptors is that their natural affinity is low. This problem has recently been overcome using phage display to increase TCR affinity up to a million-fold.
在过去二十年中，出现了越来越多的单克隆抗体，事实证明这些抗体对癌症和自身免疫性疾病均有有效的治疗作用。一种相关蛋白，即人类T细胞受体（TCR），能够针对抗体不适用的一系列新靶点发挥作用，并且正在被开发为一类新型蛋白质疗法。与抗体类似，TCR具有特定靶点，因此副作用的可能性有限；然而，这些受体可能存在的一个缺点是它们的天然亲和力较低。最近，利用噬菌体展示技术将TCR的亲和力提高了一百万倍，从而克服了这个问题。
